PTC Therapeutics presenta datos provisionales positivos del ensayo clínico PIVOT-HD en pacientes con enfermedad de Huntington
June 21, 2023 PDF Version - Dose-dependent lowering of blood Huntingtin (HTT) protein levels at 12 weeks -- Favorable tolerability profile with no treatment-related serious adverse events or NfL spikes - - Conference call and webcast to be held June 21st at 8:00 am EDT - SOUTH PLAINFIELD, N.J., June 21, 2023 /PRNewswire/ - PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared Leer más...